The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
The small study documented several cases of denervation and increased thermal thresholds in patients treated with LCIG.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers.
Vascular disease can have a negative impact on cognition and motor phenotype in PD.
Cognitive training and tDCS, alone or combined, appear to benefit cognition and QOL in Parkinson's patients
The standard MoCA evaluation was unable to predict decline in fluctuating attention and visual memory.
Over fifty percent of respondents reported using 1 or more alternative therapies.
The 4th World Parkinson Congress takes September 20-23, 2016 in Portland, Oregon.
The pathogenesis of GBA on PD is unclear, although several studies have pointed to disruptions of different molecular pathways that contribute to disease onset.
Smoking during pregnancy has been linked withlong-term neurodevelopmental abnormalities and child behavioral problems.
Patients in the treatment group experienced significant improvements at 3 months and through 12 months.
The potential role of active music therapy in ameliorating motor and nonmotor symptoms of Parkinson's disease (PD) was examined by researchers.
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Myoclonic seizures may be easily mistaken for a possible tic disorder if the proper patient monitoring is not conducted during diagnosis.
According to a 2010 report based on a survey of caregivers of people with DLB, 78% of cases were initially misdiagnosed.
The drug was generally well-tolerated among study participants.
Patients experienced a 50% improvement in tremor and motor function.
The FDA previously investigated the effects of gadolinium deposits in the brain.
The drug has a similar mechanism of action as tetrabenazine, but a different pharmacokinetic profile.
The odd relationship may have more to do with the mental disorder than the drugs.
Critics are warning to not jump to conclusions, as the results may stem from several causes.
The drug is the first of its kind to address PD psychosis without having an ill effect on motor symptoms.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Glucocerebrosidase gene mutation has been found to be strongly associated with REM sleep behavior disorder.
The authors are primarily concerned with the overlap of therapies being used in these patients.
Neurology Advisor Articles
- Migraine Relief After Chiropractic Manipulation Likely a Placebo Effect
- No Benefit for IV tPA Before Mechanical Thrombectomy in Ischemic Stroke
- Vitamin D Levels Linked to Migraine in Men
- Template Improves Quality of Report on MRI for Multiple Sclerosis
- Should EEG Periodic Discharges be Managed Similarly to Seizures?